ID

11997

Descrição

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.; ODM derived from: https://clinicaltrials.gov/show/NCT02470065 Principal Investigator: Sanjay Popat, PhD Royal Marsden NHS Foundation Trust

Link

https://clinicaltrials.gov/show/NCT02470065

Palavras-chave

Versões (1)
  1. 31/08/2015 31/08/2015 -
Transferido a

31 de agosto de 2015

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Non Small Cell Lung Cancer NCT02470065

Inglês

Eligibility Non Small Cell Lung Cancer NCT02470065

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
histological or cytological diagnosis of nsclc;
Descrição

diagnosis; NSCLC

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0011900
UMLS CUI [2]
C0007131
Patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist;
Descrição

Patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist;

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1273390
UMLS CUI [2]
C0027651
Stage I-III (T1a-3, N0-1, M0 according to UICC version 7) NSCLC by local staging criteria potentially treatable by radical (curative) surgery. Patients with T1 tumor at baseline will be limited to 20%;
Descrição

Stage I-III (T1a-3, N0-1, M0 according to UICC version 7) NSCLC by local staging criteria potentially treatable by radical (curative) surgery. Patients with T1 tumor at baseline will be limited to 20%;

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0178759
Radiologically measurable disease according to RECIST criteria 1.1; assessed by chest and upper abdomen CT scan within 2 weeks (+1 week) prior to registration); brain CT scan or MRI according to local practice
Descrição

Radiologically measurable disease according to RECIST criteria 1.1; assessed by chest and upper abdomen CT scan within 2 weeks (+1 week) prior to registration); brain CT scan or MRI according to local practice

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1513041
No prior treatment for NSCLC is allowed
Descrição

prior treatment

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1514463
Adequate tissue in terms of quality and quantity for EGFR local testing.
Descrição

Adequate tissue in terms of quality and quantity for EGFR local testing.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0034802
UMLS CUI [2]
C0022885
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI-1
C0680251
no adequate bone marrow function within 2 weeks prior to randomization
Descrição

no adequate bone marrow function within 2 weeks prior to randomization

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1389329
no adequate liver function. Patients with Gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization
Descrição

no adequate liver function. Patients with Gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0232741
no adequate renal function within 2 weeks prior to randomization
Descrição

no adequate renal function within 2 weeks prior to randomization

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0232804
known positivity to human immunodeficiency virus (hiv), hepatitis b or hepatitis c
Descrição

known positivity to human immunodeficiency virus (HIV), hepatitis B or hepatitis C

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0019699
UMLS CUI [2]
C0019158
known history of allergic reactions attributed to compounds of similar chemical or biological composition;
Descrição

known history of allergic reactions attributed to compounds of similar chemical or biological composition

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1527304
history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;
Descrição

history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0006826
Voltar ao início da página

Similar models

Eligibility Non Small Cell Lung Cancer NCT02470065

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
diagnosis; NSCLC
Item
histological or cytological diagnosis of nsclc;
boolean
C0011900 (UMLS CUI [1])
C0007131 (UMLS CUI [2])
curative treatment; Neoplasms
Item
Patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist;
boolean
C1273390 (UMLS CUI [1])
C0027651 (UMLS CUI [2])
Tumor Stage Classification
Item
Stage I-III (T1a-3, N0-1, M0 according to UICC version 7) NSCLC by local staging criteria potentially treatable by radical (curative) surgery. Patients with T1 tumor at baseline will be limited to 20%;
boolean
C0178759 (UMLS CUI [1])
measurable disease
Item
Radiologically measurable disease according to RECIST criteria 1.1; assessed by chest and upper abdomen CT scan within 2 weeks (+1 week) prior to registration); brain CT scan or MRI according to local practice
boolean
C1513041 (UMLS CUI [1])
prior treatment
Item
No prior treatment for NSCLC is allowed
boolean
C1514463 (UMLS CUI [1])
Epidermal Growth Factor Receptor; test
Item
Adequate tissue in terms of quality and quantity for EGFR local testing.
boolean
C0034802 (UMLS CUI [1])
C0022885 (UMLS CUI [2])
Item Group
Exclusion Criteria
C0680251 (UMLS CUI-1)
poor function; bone marrow
Item
no adequate bone marrow function within 2 weeks prior to randomization
boolean
C1389329 (UMLS CUI [1])
liver function
Item
no adequate liver function. Patients with Gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization
boolean
C0232741 (UMLS CUI [1])
renal function
Item
no adequate renal function within 2 weeks prior to randomization
boolean
C0232804 (UMLS CUI [1])
HIV positive; Hepatitis
Item
known positivity to human immunodeficiency virus (hiv), hepatitis b or hepatitis c
boolean
C0019699 (UMLS CUI [1])
C0019158 (UMLS CUI [2])
allergic reaction
Item
known history of allergic reactions attributed to compounds of similar chemical or biological composition;
boolean
C1527304 (UMLS CUI [1])
Malignant Neoplasms
Item
history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;
boolean
C0006826 (UMLS CUI [1])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial